MONTE ROSA THERAPEUTICS INC
GLUENASDAQTrading Snapshot
- Day Range
- $10.72 – $11.18
- 52-Week Range
- $9.68 – $25.77
- Volume (shares)
- 1,307,279
- Avg Volume (shares)
- —
- Shares Outstanding
- 85.3M
- Next Earnings
- 2026-11-05
Fundamentals Snapshot
- Annual Revenue
- $124M
- Last Q Revenue
- $9M
- P/E Ratio
- —
- P/S Ratio
- 31.7x
- EPS (TTM)
- $-1.74
- Dividend Yield
- —
- Dilution (1yr)
- +6.7%
MONTE ROSA THERAPEUTICS INC
GLUE
StockOtter · stockotter.spaceAbout MONTE ROSA THERAPEUTICS INC
Monte Rosa Therapeutics, Inc. is a biopharmaceutical company dedicated to pioneering novel, small-molecule precision medicines. Their core approach involves leveraging the body's inherent mechanisms to precisely eliminate therapeutically relevant proteins. Among their key initiatives is an oral molecular glue degrader designed to target GSPT1, a specific translational termination factor and degron-containing protein, with the aim of treating Myc-driven cancers. The company's pipeline further includes programs for CDK2 in ovarian, uterine, and breast cancers, alongside NEK7 for addressing a spectrum of inflammatory conditions such as Crohn's disease, neurodegenerative ailments, diabetes, and liver disease. Moreover, VAV1 is being explored as a target for autoimmune disorders, and BCL11A, a protein holding significant therapeutic relevance, is under investigation for hemoglobinopathies. Founded in 2019, Monte Rosa Therapeutics, Inc. operates from its headquarters in Boston, Massachusetts.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Insufficient data for all five components.
Analyst Ratings
ⓘLatest News & Updates
Monte Rosa Therapeutics (GLUE) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
Monte Rosa Therapeutics (GLUE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Monte Rosa Therapeutics Announces Milestone Achievement Associated with Second Phase 2 Clinical Study Initiation for VAV1-directed Molecular Glue Degrader MRT-6160 (DDY391)
Monte Rosa Therapeutics Announces Milestone Achievement Associated with Second Phase 2 Clinical Study Initiation for VAV1-directed Molecular Glue Degrader
Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Stock Has Consensus Target Price of $26.67 According to Analysts
Shares of Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE - Get Free Report) have earned an average rating of "Moderate Buy" from the twelve brokerages that are presently covering the stock, Marketbeat Ratings reports. One e
ImmunityBio (NASDAQ:IBRX) vs. Monte Rosa Therapeutics (NASDAQ:GLUE) Financial Survey
Monte Rosa Therapeutics (NASDAQ: GLUE - Get Free Report) and ImmunityBio (NASDAQ: IBRX - Get Free Report) are both healthcare companies, but which is the better business? We will compare the two businesses based on the s
Monte Rosa's MRT-8102 Shows Biomarker Gains in GFORCE-1 Study
Monte Rosa Therapeutics NASDAQ: GLUE reported results from GFORCE-1, a Phase I study of its NEK7-directed molecular glue degrader MRT-8102 in participants with elevated cardiovascular risk. The company said the four-week
Monte Rosa Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BOSTON, Oct. 02, 2026 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced the grant of